Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore
Autor: | Gilberto Lopes |
---|---|
Jazyk: | angličtina |
Předmět: |
medicine.medical_specialty
Cancer Research Receptor ErbB-2 Cost-Benefit Analysis Antineoplastic Agents Breast Neoplasms Antibodies Monoclonal Humanized lcsh:RC254-282 Indirect costs Breast cancer Trastuzumab Per capita Genetics Humans Medicine Productivity Average cost health care economics and organizations Neoplasm Staging Gynecology Singapore Models Statistical Cost–benefit analysis business.industry Antibodies Monoclonal lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease United States Quality-adjusted life year Italy Oncology Female business Research Article Demography medicine.drug |
Zdroj: | BMC Cancer BMC Cancer, Vol 11, Iss 1, p 178 (2011) |
ISSN: | 1471-2407 |
DOI: | 10.1186/1471-2407-11-178 |
Popis: | Background Trastuzumab has revolutionized the way we treat early Her2Neu-positive breast cancer, as it significantly improves disease-free and overall survival. Little is known about the societal costs and benefits of treatment with trastuzumab in the adjuvant setting in Southeast Asia. Methods Societal costs (benefits) were estimated as the sum of direct and indirect costs minus benefits in the base case. Direct costs were derived from 4 treatment centers in Singapore (2 private and 2 public, comprising 60-70% of all patients with cancer seen in the island-nation); indirect costs were assessed as the loss of productivity caused by the disease or treatment. Benefits to society were based on extra years of productivity, as measured by GNI per capita, resulting from the quality adjusted life-years (QALYs) saved with the use of trastuzumab as determined in the models by Kurian, Liberato and Garrison. Results Incremental costs in Singapore, in 2005 US dollars, were $26,971.05. Average Cost per QALY was $19,174.59 (Median: $18,993.70). Costs (benefits) to society ranged from a cost of $79.42 to a benefit of $9,263.06, depending on the model used (Average benefit: $4,375.89, Median $3,944.03). Sensitivity analysis ranged from a cost of $10,685.00 to a Benefit of US$17,298.79 Conclusions Treatment with adjuvant trastuzumab is likely to generate net societal economic benefits in Singapore. Nevertheless, the lower range of possible outcomes does not refute the possibility that treatment may actually generate costs. These costs however clearly fall within the usual range of acceptable cost-effectiveness. |
Databáze: | OpenAIRE |
Externí odkaz: |